Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|21|3|343-350

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.3, 2015-05, pp. : 343-350

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of Nuwiq® (human‐cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures

By  

HAEMOPHILIA, Vol. 24, Iss. 1, 2018-01 ,pp. : 70-76

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 10, 2015-10 ,pp. : 1147-1156

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 3, 2018-03 ,pp. : 340-346

John Wiley & Sons Inc

Access to resources Recommend Favorite

Break‐through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A

By  

HAEMOPHILIA, Vol. 24, Iss. 1, 2018-01 ,pp. : 120-125

John Wiley & Sons Inc

Access to resources Recommend Favorite

Allergic reaction in a cohort of haemophilia A patients using plasma‐derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII

By  

HAEMOPHILIA, Vol. 21, Iss. 4, 2015-07 ,pp. : e281-e285

John Wiley & Sons Inc

Access to resources Recommend Favorite